Investor Relations

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing a new generation of molecular glue degrader (MGD) medicines for patients living with serious diseases, including oncology, autoimmune, inflammatory, cardiovascular and cardiometabolic diseases. The Company is advancing multiple clinical programs alongside a pipeline of discovery and preclinical candidates targeting disease-driving proteins and pathways long considered undruggable. Its proprietary QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) platform integrates proprietary molecular glue libraries with proteomics, structural biology, computational chemistry, and AI/machine learning capabilities to support the discovery and development of highly differentiated MGD medicines. Monte Rosa is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.